Azacytidine in Refractory or Relapsed AML After Intensive Chemotherapy (IC): Results of the French ATU Program.

被引：5

作者：

Itzykson, Raphael ^{[1
]}

Thepot, Sylvain ^{[1
]}

Recher, Christian ^{[2
]}

Delaunay, Jacques ^{[3
]}

Quesnel, Bruno ^{[4
]}

Dreyfus, Francois ^{[5
]}

Koka, Anne Marfaing ^{[6
]}

Vey, Norbert ^{[7
]}

Stamatoullas, Aspasia ^{[8
]}

Gyan, Emmanuel ^{[9
]}

Cluzeau, Thomas ^{[10
]}

Rousselot, Philippe ^{[11
]}

Reman, Oumedaly ^{[12
]}

Plantier, Isabelle ^{[13
]}

Marolleau, Jean Pierre ^{[14
]}

More, Pierre ^{[15
]}

Wattel, Eric ^{[16
]}

Visanica, Sorin ^{[17
]}

Zerhouni, Chahinez ^{[1
]}

Bordessoule, Dominique ^{[18
]}

Ades, Lionel

Fenaux, Pierre ^{[19
,20
]}

Gardin, Claude

机构：

[1] GFM, Bobigny, France

[2] CHU Purpan, Toulouse, France

[3] CHU Nantes, F-44035 Nantes 01, France

[4] CHRU, Lille, France

[5] Hop Cochin, AP HP, F-75674 Paris, France

[6] Hop Antoine Beclere, AP HP, Clamart, France

[7] Inst J Paoli I Calmettes, F-13009 Marseille, France

[8] Ctr Henri Becquerel, F-76038 Rouen, France

[9] CHU Tours, Tours, France

[10] CHU, Nice, France

[11] CH, Versailles, France

[12] CHU Caen, F-14000 Caen, France

[13] CH, Roubaix, France

[14] CHU, Amiens, France

[15] CH, Lens, France

[16] Hop Edouard Herriot, Lyon, France

[17] CHR, Metz, France

[18] CHU, Limoges, France

[19] Univ Paris 13, Hop Avicenne, AP HP, Bobigny, France

[20] Inst Gustave Roussy, INSERM 848, Bobigny, France

来源：

BLOOD | 2009年 / 114卷 / 22期

关键词：

D O I：

10.1182/blood.V114.22.843.843

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：436 / 436

页数：1

共 50 条

[1] Azacytidine (AZA) In Relapsed MDS and AML After Allogeneic Stem Cell Transplantation (allo-HSCT): Results of the French ATU Program.
Guieze, Romain
Jouinot, Anne
Itzykson, Raphael
Thepot, Sylvain
Guillaume, Thierry
Coiteux, Valerie
Wittnebel, Sebastien
de Botton, Stephane
Dartigeas, Caroline
Sirvent, Anne
Turlure, Pascal
Bouscary, Didier
Robin, Marie
Vernant, Jean-Paul
Sutton, Laurent
Dreyfus, Francois
Bay, Jacques-Olivier
Ades, Lionel
Fenaux, Pierre
BLOOD, 2010, 116 (21) : 553 - 554
[2] Treatment of AML with azacytidine (AZA): Current results of the french ATU program
Fabre, Claire
Gardin, Claude
Mbida, Rose-Marie
Quesnel, Bruno
Dreyfus, Frarvois
Isnard, Framoise
Mannone, Lionel
Legros, Laurence
Prebet, Thomas
Vey, Norbert
Beyne-Rauzy, Dile
Dalbies, Florence
Cheze, Stephane
Delaunay, Jacques
Fruchart, Christophe
Koka, Anne Marfaing
Stamatoullas, Aspasia
Bordessoule, Dominique
Cambier, Nathalie
Comillon, Jerome
Dartigeas, Caroline
Delmas-Marsalet, Beatrice
Fenaux, Pierre
BLOOD, 2007, 110 (11) : 547A - 548A
[3] Azacytidine (AZA) as First Line Therapy in AML: Results of the French ATU Program
Thepot, Sylvain
Itzykson, Raphael
Seegers, Valerie
Recher, Christian
Quesnel, Bruno
Delaunay, Jacques
Cluzeau, Thomas
Koka, Anne Marfaing
Stamatoullas, Aspasia
Chaury, M. P.
Dartigeas, Caroline
Cheze, Stephane
Salanoubat, Celia
Morel, Pierre
Plantier, Isabelle
Taksin, Anne-Laure
Marolleau, Jean Pierre
Pautas, Cecile
Wattel, Eric
Isnard, Francoise
Sanhes, Laurence
Harel, Stephanie
de Botton, Stephane
Chait, Yasmine
Uzunov, Madalina
Guerci, Agnes
Dahoun, Mehdi
Vey, Norbert
Dombret, Herve
Dreyfus, Francois
Ades, Lionel
Fenaux, Pierre
Gardin, Claude
BLOOD, 2009, 114 (22) : 347 - 347
[4] Treatment of high risk MDS and AMLPost-MDS with azacytidine (AZA): Preliminary results of the French ATU program.
Fabre, Claire
Chermat, Fatsiha
Legros, Laurence
Park, Sophie
Dreyfus, Francois
Isnard, Francoise
Nowak, Florence
Marfaing, Anne
de Botton, Stephane
Noel, Marie-Pierre
Fruchart, Christophe
Prebet, Thomas
Vey, Norbert
Dartigeas, Caroline
Fenaux, Pierre
BLOOD, 2006, 108 (11) : 753A - 753A
[5] Response to Azacytidine (AZA) in MDS or AML with Del 5q: Current Results of the French ATU Program
Itzykson, Raphael
Thepot, Sylvain
Fabre, Claire
Dreyfus, Francois
Quesnel, Bruno
Wattel, Eric
de Botton, Stephane
Pilorge, Sylvain
Dartigeas, Caroline
Stamatoullas, Aspasia
Prebet, Thomas
Ojeda-Uribe, Mario
Cheze, Stephane
Tournilhac, Olivier
Solary, Eric
Damaj, Gandhi
Tertian, Gerard
Himberlin, Chantal
Mbida, Rose-Marie
Beve, Blandine
Ades, Lionel
Gardin, Claude
Fenaux, Pierre
BLOOD, 2008, 112 (11) : 927 - 927
[6] BENEFITS OF THE USE OF AZACITDINE IN PATIENTS WITH AML REFRACTORY OR RELAPSED AFTER INTENSIVE CHEMOTHERAPY
Giagnuolo, G.
Cerchione, C.
Angelillo, P.
Vitagliano, O.
Pugliese, N.
Marano, L.
Battipaglia, G.
Avilia, S.
Alfinito, F.
Cerciello, Giuseppe
Pane, Fabrizio
HAEMATOLOGICA, 2013, 98 : 307 - 308
[7] Treatment of high risk mds and aml post-MDS with azacytidine (AZA): Current results of the French ATU program
Sebert, M.
Hernandez, E.
Chermat, F.
Bordessoule, D.
Chaury, M. P.
Dartigeas, C.
De Bottom, S.
Dreyfus, F.
Legros, L.
Mannone, L.
Marfaing-Koka, A.
Noel, M. P.
Park, S.
Prebet, T.
Stamatoullas, A.
Vey, N.
Fenaux, P.
Fabre, C.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 158 - 159
[8] Treatment of high risk MDS and AML post-MDS with azacytidine (AZA): current results of the French ATU program
Fabre, C.
Sebert, M.
Hernandez, E.
Chermat, F.
Bordessoule, D.
Chaury, M. P.
Dartigeas, C.
de Botton, S.
Dreyfus, F.
Legros, L.
Mannone, L.
Marfaing-Koka, A.
Noeel, M. P.
Park, S.
Prebet, T.
Stamatoullas, A.
Vey, N.
Fenaux, P.
LEUKEMIA RESEARCH, 2007, 31 : S122 - S122
[9] 5-Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy
Ivanoff, Sarah
Gruson, Berengere
Chantepie, Sylvain P.
Lemasle, Emilie
Merlusca, Lavinia
Harrivel, Veronique
Charbonnier, Amandine
Votte, Patrick
Royer, Bruno
Marolleau, Jean-Pierre
AMERICAN JOURNAL OF HEMATOLOGY, 2013, 88 (07) : 601 - 605
[10] Efficacy and Safety of Thalidomide In Mantle Cell Lymphoma: Results of the French ATU Program.
Harel, Stephanie
Bachy, Emmanuel
Haioun, Corinne
Gyan, Emmanuel
Damaj, Gandhi
Morineau, Nadine
Arnulf, Bertrand
Hermine, Olivier
Delarue, Richard
BLOOD, 2010, 116 (21) : 749 - 749

← 1 2 3 4 5 →